# Codex Review: medical_monitoring_subject_risk_card_source_grounding_20260802

Date: 2026-08-02 09:53 CST
Route: Codex direct; no delegated agent, conference, or Hermes dispatch.
Runner-owned report: `runs/codex_medical_monitoring_subject_risk_card_source_grounding_20260802.md`

## Verdict

**PASS — bounded source-grounding presentation correction.** The unsupported
hardcoded safety topic was removed; the card now exposes only supplied AE,
explicitly linked laboratory, prompt, status, locator, and safety-reference
fields.

## Boundary Check

- Codex performed the work directly; no delegated agent was used.
- Changed product source is limited to
  `frontend/src/features/medical-monitoring/medicalMonitoringSubjectModels.mjs`
  and its existing Node test. Task context/review/metrics and the task records
  are the only added evidence surfaces; the Vite build updated existing
  generated `frontend/dist/*` output.
- `App.jsx`, `styles.css`, API/backend, SQLite, provider, runtime, browser,
  B6/C13/C14, real projects, and medical-writing files were not modified.

## Codex Verification

- Focused model test passed.
- All 22 medical-monitoring Node contract files passed.
- Python frontend contracts passed 61/61.
- Vite production build passed (`1925 modules transformed`); the existing
  large-chunk warning remains.
- Source scan confirms the removed unsupported phrase is absent from the model
  and test source.
- No browser/runtime check was run because 8911/5174 remain stopped and the
  B6/C13 authority gates are closed.

## Implementation Review

- `displayEvidenceValue` prevents object coercion and retains explicit locator
  mappings in a compact UI string.
- AE-to-laboratory display requires an event-ID/linked-ID relation or shared
  risk ID; same-visit coincidence is intentionally insufficient.
- Safety basis text is emitted only from explicit event/prompt fields. No
  title-to-safety-topic inference, CTCAE threshold, IB interpretation, or
  relationship conclusion was added.
- Empty CM/PD states now say evidence is unavailable rather than implying a
  current-rule hit or exclusion-standard violation.
- The change leaves the existing card structure and CM/PD behavior intact.

## Residual Risk

- The card title remains a product-level risk category and its underlying
  rule/authority is not validated by this slice.
- Real source availability, protocol/IB evidence, clinical review, browser
  rendering, B6 reviewer outcomes, runtime activation, three-project LOOP,
  UAT, and commercial readiness remain unverified and blocked by existing
  gates.
